Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02840123 : Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines
PhasePhase 1
AgesMin: 3 Years Max: 18 Years
Eligibility
Inclusion Criteria:

- Newly diagnosed DIPG Patients without progressive disease

- Aged between 3 and 18 yo Lansky scale >50 (Karnofsky for patients aged more than 16
yr)

- Life expectancy > 8 weeks

- Preserved bone marrow function Normal hepatic and renal function

Exclusion Criteria:

- Impossibility to perform aphaeresis

- Patient participation of other experimental study within the last 3 months

- Patient under antitumor treatment in the last 4 weeks

- Co-morbidity that does not allow the study treatment

- Patients requiring > 2mg/day of dexamethasone treatment Corticoid-dependent patients

- Patients under uncontrolled infection

- Positive serologies of HIV, hepatitis C virus (HCV) or hepatitis B virus (HBV)
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02840123      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740